11 completed, 6 terminated, 3 active not recruiting, 1 recruiting. 21 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 11, Terminated 6, Active not recruiting 3, Recruiting 1 |
Follow Pulmonary Eosinophilia: new trials by email Literature Review of Pulmonary Eosinophilia trials Research Report on Pulmonary Eosinophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Depemokimab in Participants of 6 to 11 Years of Age Depemokimab - Asthma | Phase 3 | Recruiting | GlaxoSmithKline | 34 | 2026-06-25 | 2026-08-26 |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment ICS-LABA, benralizumab, Placebo for Benralizumab - Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 130 | 2025-03-28 | 2026-10-16 |
| SIM0718 Treatment of Asthma Clinical Study SIM0718 injection, SIM0718 injection of placebo - Asthma; Eosinophilic | Phase 3 | Active not recruiting | Simcere Pharmaceutical Co., Ltd | 418 | 2024-06-23 | 2026-10-21 |
| Phase III Long-Term Extension Study With Dexpramipexole Dexpramipexole Dihydrochloride - Eosinophilic Asthma | Phase 3 | Terminated | Areteia Therapeutics | 509 | 2024-06-12 | 2025-12-15 |
| STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma Benralizumab - Severe Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 504 | 2024-02-28 | 2026-09-03 |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma Benralizumab, Placebo - Asthma | Phase 3 | Active not recruiting | AstraZeneca | 94 | 2023-04-05 | 2026-10-28 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 654 | 2023-03-27 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 1061 | 2023-01-30 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Active not recruiting | Areteia Therapeutics | 600 | 2023-01-30 | 2025-09-05 |
| Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma Treatment A, Treatment B, Treatment C - Asthma; Eosinophilic | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 810 | 2019-08-28 | 2022-04-08 |
| Study of Mepolizumab Autoinjector in Asthmatics Mepolizumab - Asthma | Phase 3 | Completed | GlaxoSmithKline | 159 | 2017-05-04 | 2023-06-28 |
| Study of Mepolizumab Safety Syringe in Asthmatics Mepolizumab - Asthma | Phase 3 | Completed | GlaxoSmithKline | 56 | 2017-02-01 | 2019-07-23 |
| Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Mepolizumab 100mg, Placebo - Asthma | Phase 3 | Completed | GlaxoSmithKline | 306 | 2016-01-07 | 2020-02-05 |
| Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Mepolizumab, Placebo - Asthma | Phase 3 | Terminated | Johannes Gutenberg University Mainz | 29 | 2015-11-17 | 2017-07-13 |
| Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Mepolizumab, Placebo, SOC - Asthma | Phase 3 | Completed | GlaxoSmithKline | 556 | 2014-12-11 | 2018-08-06 |
| A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Mepolizumab, SOC - Asthma | Phase 3 | Completed | GlaxoSmithKline | 339 | 2014-05-29 | 2019-12-03 |
| Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 511 | 2012-02-01 | 2016-06-27 |
| Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Reslizumab - Eosinophilic Asthma | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 1052 | 2011-06-01 | 2016-06-06 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 489 | 2011-04-01 | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 464 | 2011-03-01 | 2021-11-09 |
Showing 20 of 21. Sign in to see all of them.
Asthma (12)
Eosinophilia (21) · Hematologic Diseases (21) · Hemic and Lymphatic Diseases (21) · Hypereosinophilic Syndrome (21) · Leukocyte Disorders (21) · Lung Diseases (21) · Respiratory Tract Diseases (21) · Bronchial Diseases (12) · Hypersensitivity (12) · Hypersensitivity, Immediate (12) · Immune System Diseases (12) · Lung Diseases, Obstructive (12) · Respiratory Hypersensitivity (12)
mepolizumab (6) · Antibodies, Monoclonal, Humanized (5) · reslizumab (5) · benralizumab (3)
GlaxoSmithKline (6) · Teva Branded Pharmaceutical Products R&D, Inc. (5) · Areteia Therapeutics (4) · AstraZeneca (3) · Chiesi Farmaceutici S.p.A. (1) · Johannes Gutenberg University Mainz (1) · Simcere Pharmaceutical Co., Ltd (1)
United States (17) · Argentina (11) · Canada (11) · France (9) · Germany (9) · Poland (9) · South Korea (9) · Ukraine (9) · United Kingdom (9) · Russia (8) · Brazil (7) · Mexico (7) · Netherlands (6) · Romania (6) · Spain (6)
HuaHao Shen, Professor (1) · Michael E. Wechsler, MD (1) · Min Zhang, Professor (1) · Mona Bafadhel, MD (1) · Pierluigi Paggiaro, MD (1) · Sady Alpizar, MD (1) · Salman Siddiqui, MD (1) · Stephanie Korn, MD (1)
PMID 39393433, PMID 25736990, PMID 28159511, PMID 30193936, PMID 30346831, PMID 30964365, PMID 31262379, PMID 31626990, PMID 27018175, PMID 27056586, PMID 28395936, PMID 29949045, PMID 31047111, PMID 31251094, PMID 31507641, PMID 34098955, PMID 34158028, PMID 34172470
2015 (2), 2016 (2), 2014 (1), 2018 (1), 2023 (1)